CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in <i>KRAS</i> wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial

Yuankai Shi, Jin Li, Jianming Xu et al.|癌症：英文版|2019

Cited by 11